GlassScriptPhysician profile
Tara L Lawless
NPI 1649685611
$4,068.01
in general payments reported to CMS, 2019-2025
21 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $570 · 2023: $349 · 2024: $787 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,679 · Travel and Lodging: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.66 |
| Travel and Lodging | $1,334.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $3,401.51 | 2021-2025 | Puraply Wound Matrix, Cygnus Dual, Affinity |
| Abbvie INC. | $109.71 | 2021-2024 | |
| Lilly USA, LLC | $91.43 | 2021-2024 | Mounjaro |
| Alkermes, INC. | $58.06 | 2021-2022 | |
| Kerecis Limited | $46.59 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Janssen Pharmaceuticals, INC | $41.01 | 2021-2022 | |
| Novo Nordisk INC | $39.68 | 2021-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $37.20 | 2021-2022 | |
| Astellas Pharma US INC | $28.83 | 2023-2024 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $27.47 | 2022 | |
| Integra Lifesciences Corporation | $26.56 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Abbott Laboratories | $23.08 | 2024 | Freestyle Libre 3 |
| Convatec INC. | $21.33 | 2024 | |
| Vyera Pharmaceuticals, LLC | $19.40 | 2022 | |
| Paratek Pharmaceuticals, INC. | $16.67 | 2024 | Nuzyra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $15.45 | 2022 | |
| Reprise Biomedical, INC. | $14.50 | 2025 | Miro3d |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2022 | |
| Jazz Pharmaceuticals INC. | $13.37 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.68 | 2021 | |
| Genentech USA, INC. | $9.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Lawless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.